Table 1.
Growth properties of 1205 Lu, A375M, and UACC 903 cells treated with scrambled siRNA or siRNA against B-RAF, MEK, ERK, or CYCLIN D1
| SiRNA treatment | Melanoma cell line doubling time in vitro (hours ± SE) |
|||||
|---|---|---|---|---|---|---|
| 1205 Lu | A375M | UACC 903 | ||||
| Controls | ||||||
| Scrambled | 38 ± 3 | 33 ± 2 | 26 ± 1 | |||
| Universal buffer | 44 ± 7 | 32 ± 3 | 28 ± 0 | |||
| Average | 41 | 33 | 27 | |||
| Experimental | ||||||
| B-Raf mut (A) | 53 ± 10 | ↑29% | 46 ± 6 | ↑39% | 38 ± 3 | ↑41% |
| Mek 1 | 41 ± 3 | NC | 36 ± 3 | NC | 32 ± 0 | ↑19% |
| Mek 2 | 39 ± 3 | NC | 29 ± 2 | NC | 26 ± 0 | NC |
| Mek 1 + Mek 2 | 60 ± 9 | ↑46% | 39 ± 2 | ↑18% | 44 ± 5 | ↑63% |
| Erk 1 | 53 ± 0 | ↑29% | 34 ± 4 | NC | 26 ± 0 | NC |
| Erk 2 | 43 ± 4 | NC | 34 ± 2 | NC | 31 ± 1 | ↑15% |
| Erk 1 + Erk 2 | 64 ± 3 | ↑56% | 40 ± 2 | ↑18% | 37 ± 1 | ↑37% |
| Cyclin D1 | 52 ± 0 | ↑27% | 36 ± 3 | NC | 29 ± 0 | NC |
| Average | 51 | ↑24% | 36 | NC | 33 | ↑22% |
NOTE: To the right of each experimental value is shown relative changes in proliferative capacity between the control average and experimental value; NC, no significant change between control average and experimental value (i.e., a difference of ≤3 hours).